[
  {
    "ts": null,
    "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
    "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
    "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743631415,
      "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
      "id": 133695061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
      "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know",
    "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=1325ba393c4eb9535ea73a28c927b1a27122bae94f8667bbcd5138bef637ea1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743630315,
      "headline": "Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know",
      "id": 133695093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=1325ba393c4eb9535ea73a28c927b1a27122bae94f8667bbcd5138bef637ea1e"
    }
  },
  {
    "ts": null,
    "headline": "My Top 10 High-Yield Dividend Stocks For April 2025: One Yields 8%-Plus",
    "summary": "Discover 10 top high-yield dividend stocks for April 2025. With a 5.30% yield & 8.33% growth rate, learn how to build wealth through income & growth. Read the full list of stock picks here.",
    "url": "https://finnhub.io/api/news?id=42b57e04216583dea7d71f943f669620bd0d35bd96db90234ce5630a8679b7e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743616800,
      "headline": "My Top 10 High-Yield Dividend Stocks For April 2025: One Yields 8%-Plus",
      "id": 133682661,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184220584/image_2184220584.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 10 top high-yield dividend stocks for April 2025. With a 5.30% yield & 8.33% growth rate, learn how to build wealth through income & growth. Read the full list of stock picks here.",
      "url": "https://finnhub.io/api/news?id=42b57e04216583dea7d71f943f669620bd0d35bd96db90234ce5630a8679b7e9"
    }
  },
  {
    "ts": null,
    "headline": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
    "summary": "Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer’s products, like Eliquis (2027 to 2029) and Ibrance (2027), face “patent cliffs.” That means their time for market exclusivity is",
    "url": "https://finnhub.io/api/news?id=4aa488ac19b07f7b0bec5892050d6a7eb611f188f8318e659fb8bfcc78d845f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743612204,
      "headline": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
      "id": 133669553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer’s products, like Eliquis (2027 to 2029) and Ibrance (2027), face “patent cliffs.” That means their time for market exclusivity is",
      "url": "https://finnhub.io/api/news?id=4aa488ac19b07f7b0bec5892050d6a7eb611f188f8318e659fb8bfcc78d845f9"
    }
  },
  {
    "ts": null,
    "headline": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
    "summary": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
    "url": "https://finnhub.io/api/news?id=611d6c8d7611d0acc68c83eed246c9f8d45eefbfc4007a723fb61da60186c604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743601380,
      "headline": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
      "id": 133669379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
      "url": "https://finnhub.io/api/news?id=611d6c8d7611d0acc68c83eed246c9f8d45eefbfc4007a723fb61da60186c604"
    }
  },
  {
    "ts": null,
    "headline": "Proxy adviser ISS recommends against Pfizer executive pay proposal",
    "summary": "(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term awards to its CEO and others.  The modifications, including repeated changes to Pfizer's cash flow targets, and a lack of clarity about certain pipeline goals are concerning and undermine a \"pay-for-performance philosophy\", ISS said.  Annual incentives for executives are tied to achieving three financial goals, and payouts can be 30 percentage points higher or lower based on pipeline and ESG-related goals achieved, ISS said.",
    "url": "https://finnhub.io/api/news?id=d94dcb1e8126bba020cfb06fbbd48637abcf5fbee7e881015d8c503141a79906",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743599420,
      "headline": "Proxy adviser ISS recommends against Pfizer executive pay proposal",
      "id": 133669557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term awards to its CEO and others.  The modifications, including repeated changes to Pfizer's cash flow targets, and a lack of clarity about certain pipeline goals are concerning and undermine a \"pay-for-performance philosophy\", ISS said.  Annual incentives for executives are tied to achieving three financial goals, and payouts can be 30 percentage points higher or lower based on pipeline and ESG-related goals achieved, ISS said.",
      "url": "https://finnhub.io/api/news?id=d94dcb1e8126bba020cfb06fbbd48637abcf5fbee7e881015d8c503141a79906"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=56e02e3b1c81a6a8e39416df56beba4594153303f4b57cf471059b91666cffdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743598809,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 133669559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=56e02e3b1c81a6a8e39416df56beba4594153303f4b57cf471059b91666cffdd"
    }
  },
  {
    "ts": null,
    "headline": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
    "summary": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
    "url": "https://finnhub.io/api/news?id=0967859286d023ee52c3082f839e48fe59e646ecc75f2163b728f1f3a4c60d63",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743594600,
      "headline": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
      "id": 134149080,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
      "url": "https://finnhub.io/api/news?id=0967859286d023ee52c3082f839e48fe59e646ecc75f2163b728f1f3a4c60d63"
    }
  },
  {
    "ts": null,
    "headline": "PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo",
    "summary": "The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.",
    "url": "https://finnhub.io/api/news?id=bdff497591b532afed07447fa207f50445bbbe378775d977fa0be861bbef52c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743593820,
      "headline": "PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo",
      "id": 133669560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.",
      "url": "https://finnhub.io/api/news?id=bdff497591b532afed07447fa207f50445bbbe378775d977fa0be861bbef52c4"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
    "summary": "The latest investor updates on stocks that are trending on Wednesday.",
    "url": "https://finnhub.io/api/news?id=7df74f9acfb8cb98459bcb013fcedf07bd1896e6e30e1921f04c41a816108a36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743586874,
      "headline": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
      "id": 133666083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Wednesday.",
      "url": "https://finnhub.io/api/news?id=7df74f9acfb8cb98459bcb013fcedf07bd1896e6e30e1921f04c41a816108a36"
    }
  }
]